Related Experiment Video
Updated: May 31, 2026
08:36
In Vitro Assay to Study Tumor-macrophage Interaction
Published on: August 1, 2019
Macrophage-Centric Phenotypic Screening Identifies Tetrazolone-Based HDAC6 Inhibitors That Reprogram the Tumor Immune
Nithya Gajendran1, Manasa Suresh1, Sebastian J Marquez R2
1Georgetown University, Washington, District of Columbia 20057, United States.
Journal of Medicinal Chemistry
|May 29, 2026
Summary
Researchers developed a new screening platform to find drugs that reprogram tumor-associated macrophages (TAMs) for better cancer immunotherapy. A novel HDAC6 inhibitor, SM-06-09, showed promise in enhancing anti-tumor immunity.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Tumor-associated macrophages (TAMs) significantly influence the tumor microenvironment (TME) and immunotherapy response.
- Current drug screening often overlooks immune cell modulation, focusing instead on tumor cell killing.
Purpose of the Study:
- To establish a macrophage-centric screening platform for identifying selective HDAC6 inhibitors.
- To develop novel compounds that reprogram TAMs towards an antitumor phenotype.
Main Methods:
- Developed a phenotypic screening platform targeting macrophage function.
- Synthesized novel tetrazolone-based HDAC6 inhibitors, including SM-06-09.
- Evaluated SM-06-09's effects on macrophage phagocytosis, antigen presentation, T-cell activation, and in vivo tumor suppression.
Main Results:
- SM-06-09 demonstrated potent and selective HDAC6 inhibition with minimal cytotoxicity.
- In vitro studies showed SM-06-09 enhanced macrophage phagocytosis and T-cell activation.
- In vivo, SM-06-09 suppressed melanoma growth, promoted M1-like TAM polarization, and improved efficacy when combined with anti-PD-1 therapy.
Conclusions:
- The study presents a functional screening framework for discovering immunomodulatory compounds.
- Macrophage-targeted HDAC6 inhibitors, like SM-06-09, hold clinical potential as adjuncts to immune checkpoint blockade therapy.
